<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05011227</url>
  </required_header>
  <id_info>
    <org_study_id>rNPC-SA-Neo-Cam-V1</org_study_id>
    <nct_id>NCT05011227</nct_id>
  </id_info>
  <brief_title>Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma</brief_title>
  <official_title>A Prospective, Single-arm, Multi-center Clinical Study of Camrelizumab and Chemotherapy Combined With Endoscopic Surgery in the Treatment of Recurrent Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eye &amp; ENT Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eye &amp; ENT Hospital of Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the effect of Camrelizumab and chemotherapy combining with endoscopic surgery in&#xD;
      the treatment of recurrent nasopharyngeal carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2021</start_date>
  <completion_date type="Anticipated">August 10, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 10, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of first treatment until the date of death from any cause, up to 4 years.</time_frame>
    <description>2 year Overall Survival rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local recurrence free survival</measure>
    <time_frame>From date of first treatment until the date of local recurrence or death from any cause, up to 4 years.</time_frame>
    <description>the date of first treatment to local failure or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From date of first treatment until the date of disease progression or death from any cause, up to 4 years.</time_frame>
    <description>the date of first treatment to the first recording of disease progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of negative margin</measure>
    <time_frame>At the time of pathology reporting, util the pathology report of last subject was completed, up to 2.5 years.</time_frame>
    <description>negative margin rate according to pathology report</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distant metastasis free survival</measure>
    <time_frame>From date of first treatment until the date of distant metastasis or death from any cause, up to 4 years.</time_frame>
    <description>the date of first treatment to distant metastasis or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pathologic complete remission</measure>
    <time_frame>At the time of pathology reporting,util the pathology report of last subject was completed, up to 2.5 years.</time_frame>
    <description>pathologic complete remission</description>
  </secondary_outcome>
  <other_outcome>
    <measure>quality of life-（EORTC QLQ) - C30 version3.0</measure>
    <time_frame>From date of first treatment to the end of study, at each visit, up to 4 years.</time_frame>
    <description>using European Organisation for Research and Treatment of Cancer quality of life questionaire（EORTC QLQ) - C30 version3.0. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.</description>
  </other_outcome>
  <other_outcome>
    <measure>quality of life-（EORTC QLQ) - H&amp;N35</measure>
    <time_frame>From date of first treatment to the end of study, at each visit, up to 4 years.</time_frame>
    <description>using European Organisation for Research and Treatment of Cancer quality of life questionaire（EORTC QLQ）- H&amp;N35，All of the scales and single-item measures range in score from 0 to 100. For all the scales and single-items a high score represents a high level of symptomatology or problems.</description>
  </other_outcome>
  <other_outcome>
    <measure>adverse effect</measure>
    <time_frame>From date of first treatment to the end of study, up to 4 years.</time_frame>
    <description>Using CTCAE Version5.0 to evaluate related adverse effect</description>
  </other_outcome>
  <other_outcome>
    <measure>immune related adverse effect</measure>
    <time_frame>From date of first treatment to the end of study, up to 4 years.</time_frame>
    <description>Using CTCAE Version5.0 to evaluate immune related adverse effect</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Recurrent Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Camrelizumab and chemotherapy combined with endoscopic surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Camrelizumab and chemotherapy combined with endoscopic surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>2 cycles before endoscopic surgery and one year after</description>
    <arm_group_label>Camrelizumab and chemotherapy combined with endoscopic surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>2 cycles before endoscopic surgery, with or without after surgery</description>
    <arm_group_label>Camrelizumab and chemotherapy combined with endoscopic surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endoscopic surgery</intervention_name>
    <description>standard endoscopic surgery for recurrent nasopharyngeal carcinoma</description>
    <arm_group_label>Camrelizumab and chemotherapy combined with endoscopic surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically confirmed recurrent nasopharyngeal carcinoma&#xD;
&#xD;
          -  American Joint Committee on Cancer recurrent rT2(recurrent T2)(including deep&#xD;
             parapharyngeal space), recurrent T3, recurrent T4 which can be surgically removed&#xD;
&#xD;
          -  Age ≥18 years old&#xD;
&#xD;
          -  Informed consent signed&#xD;
&#xD;
          -  With or without lymph node metastasis, which can be surgically removed&#xD;
&#xD;
          -  No massive hemorrhage risk recently&#xD;
&#xD;
          -  No distant metastasis&#xD;
&#xD;
          -  ≥6 months from initial radiotherapy to recurrence&#xD;
&#xD;
          -  Radical radiation only once&#xD;
&#xD;
          -  Sufficient organ function&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group score 0-2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  With a history of allergic to platinum drugs and similar compounds&#xD;
&#xD;
          -  Evidence of distant metastasis or radiation encephalopathy or leptomeningeal disease&#xD;
             (LMD)&#xD;
&#xD;
          -  Have received radioactive seed implantation in the treatment area&#xD;
&#xD;
          -  Suffer from uncontrolled disease which could interfere with treatment&#xD;
&#xD;
          -  Suffered from another malignant tumor or multiple primary tumors at the same time&#xD;
             within 5 years (excluding fully treated basal cell or squamous cell skin cancer,&#xD;
             cervical cancer in situ, etc.)&#xD;
&#xD;
          -  The patient has surgical contraindications: such as severe cardiopulmonary disease,&#xD;
             coagulation dysfunction and so on&#xD;
&#xD;
          -  The patients have autoimmune diseases&#xD;
&#xD;
          -  The patient is using immunosuppressive agents or systemic glucocorticoid to achieve&#xD;
             the purpose of immunosuppression (dose&gt;10mg/day prednisone or other), and continues to&#xD;
             use it within 2 weeks before the first administration&#xD;
&#xD;
          -  Severe allergic reaction to other monoclonal antibodies&#xD;
&#xD;
          -  Previously received PD-1 monoclonal antibody, CTLA-4 monoclonal antibody (or any other&#xD;
             antibody that acts on T cell co-stimulation or checkpoint pathway) treatment&#xD;
&#xD;
          -  Live vaccines have been inoculated within 4 weeks before the first administration or&#xD;
             during the study period&#xD;
&#xD;
          -  The patient has any situation that may hinder study compliance or the safety during&#xD;
             the study period&#xD;
&#xD;
          -  Existence of serious neurological or psychiatric diseases, such as dementia and&#xD;
             seizures&#xD;
&#xD;
          -  Uncontrolled active infection&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Those who have no personal freedom and independent capacity for civil conduct&#xD;
&#xD;
          -  There are other situations that are not suitable for entry into the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongmeng Yu, MD,PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eye&amp;ENT Hospital,Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaole Song, MD</last_name>
    <phone>15821388769</phone>
    <email>jxfxsxl@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Desheng Wang, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Haichun Lai, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Desheng Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujian Provincial Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shaopeng Huang</last_name>
    </contact>
    <investigator>
      <last_name>Shaopeng Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shenzhen Second People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yongtian Lu</last_name>
    </contact>
    <investigator>
      <last_name>Yongtian Lu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The People's Hospital of Guangxi Zhuang Autonomous Region</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jingjin Weng, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Shenhong Qu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jing Ye, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jing Ye</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eye&amp; ENT Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Yan, MD</last_name>
      <phone>13761720601</phone>
      <email>yanl13@fudan.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Xiaoshen Wang, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Zhongshan Hospital,Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xinsheng Huang</last_name>
    </contact>
    <investigator>
      <last_name>Xinsheng Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 7, 2021</study_first_submitted>
  <study_first_submitted_qc>August 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endoscopic surgery</keyword>
  <keyword>Inductive chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

